Dementia is a frequent problem encountered in advanced stages of Parkinson disease (PD).
In recent years, research has focused on the pre-dementia stages of cognitive impairment in …

Importance Imaging biomarkers in Parkinson disease (PD) are increasingly important for
monitoring progression in clinical trials and also have the potential to improve clinical care …

Parkinson's disease (PD) and atypical Parkinsonian syndromes are progressive
heterogeneous neurodegenerative diseases that share clinical characteristic of …

Two centuries ago in 1817, James Parkinson provided the first medical description of
Parkinson's disease, later refined by Jean-Martin Charcot in the mid-to-late 19th century to …

Background Cognitive decline occurs frequently in Parkinson's disease (PD), which greatly
decreases the quality of life of patients. However, the mechanisms remain to be investigated …

Mild cognitive impairment in Parkinson's disease is associated with progression to dementia
(Parkinson's disease dementia) in a majority of patients. Determining structural imaging …

Abstract See Gratwicke and Foltynie (doi: 10.1093/brain/awx333) for a scientific commentary
on this article. Cognitive impairments are a prevalent and disabling non-motor complication …

There is increasing evidence of prodromal manifestation of neuropsychiatric symptoms in a
variety of neurodegenerative diseases such as Parkinson's disease (PD) and Huntington's …

The current review summarizes the current knowledge on longitudinal cortical and
subcortical grey and white matter MRI findings assessed using T1-weighted and one-tensor …

Mild cognitive impairment (PD-MCI) and dementia (PDD) are among the most frequent non-
motor symptoms in Parkinson's disease (PD). PD-MCI is six times more likely than age …